HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins

Histone deacetylase 2 (HDAC2) is crucial for embryonic development, affects cytokine signaling relevant for immune responses, and is often significantly overexpressed in solid tumors, but little is known of its role in human lung cancer. In this study, we demonstrated the aberrant expression of HDAC2 in lung cancer tissues and investigated oncogenic properties of HDAC2 in human lung cancer cell lines. HDAC2 inactivation resulted in regression of tumor cell growth and activation of cellular apoptosis via p53 and Bax activation and Bcl2 suppression. In cell cycle regulation, HDAC2 inactivation caused induction of p21WAF1/CIP1 expression, and simultaneously suppressed the expressions of cyclin E2, cyclin D1, and CDK2, respectively. Consequently, this led to the hypophosphorylation of pRb protein in G1/S transition and thereby inactivated E2F/DP1 target gene transcriptions of A549 cells. In addition, we demonstrated that HDAC2 directly regulated p21WAF1/CIP1 expression in a p53‐independent manner. However, HDAC1 was not related to p21WAF1/CIP1 expression and tumorigenesis of lung cancer. Lastly, we observed that sustained‐suppression of HDAC2 in A549 lung cancer cells attenuated in vitro tumorigenic properties and in vivo tumor growth of the mouse xenograft model. Taken together, we suggest that the aberrant regulation of HDAC2 and its epigenetic regulation of gene transcription in apoptosis and cell cycle components play an important role in the development of lung cancer. J. Cell. Biochem. 113: 2167–2177, 2012. © 2012 Wiley Periodicals, Inc.

[1]  A. Bird,et al.  Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. , 1999, Genes & development.

[2]  M. Carducci,et al.  Acetylation and Histone Deacetylase Inhibitors in Cancer , 2006, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[3]  A. Borczuk,et al.  Expression of syndecan‐1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma , 2004, Cancer.

[4]  O. Witt,et al.  HDAC family: What are the cancer relevant targets? , 2009, Cancer letters.

[5]  Ivan V. Gregoretti,et al.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.

[6]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[7]  R. Yarden,et al.  BRCA1 interacts with components of the histone deacetylase complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  E. Seto,et al.  Histone deacetylases and cancer , 2007, Oncogene.

[9]  John H. White,et al.  Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. , 2003, Molecular cell.

[10]  J. Eun,et al.  Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate. , 2005, Biochemical and Biophysical Research Communications - BBRC.

[11]  Y. Yatabe,et al.  Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients , 2004, International journal of cancer.

[12]  Charles A Powell,et al.  Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. , 2003, The American journal of pathology.

[13]  J. Eun,et al.  Increased Expression of Histone Deacetylase 2 is Found in Human Hepatocellular Carcinoma , 2006 .

[14]  M. Salto‐Tellez,et al.  Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 , 2005, Cell Death and Differentiation.

[15]  V. Richon,et al.  Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.

[16]  E. Seto,et al.  HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention , 2007, Oncogene.

[17]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[18]  W. Weichert HDAC expression and clinical prognosis in human malignancies. , 2009, Cancer letters.

[19]  Tony Kouzarides,et al.  Retinoblastoma protein recruits histone deacetylase to repress transcription , 1998, Nature.

[20]  Suk Woo Nam,et al.  Increased expression of histone deacetylase 2 is found in human gastric cancer , 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[21]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[22]  D. Saur,et al.  HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA , 2009, Gut.

[23]  Ping Zhu,et al.  Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. , 2004, Cancer cell.

[24]  Delin Chen,et al.  Deacetylation of p53 modulates its effect on cell growth and apoptosis , 2000, Nature.

[25]  S. Schreiber,et al.  A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p , 1996, Science.

[26]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.